Clincosm LogoSign in Get a demo

Female Sexual Dysfunction in Breast Cancer Patients

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03153631
Collaborator
(none)
75
Enrollment
17
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females world wide. breast cancer alone accounts for 25% of all cancer cases and 15% of all cancer deaths among females.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In Egypt, cancer breast is one of the commonest cancers among females representing 38.8%.cancer breast among females ranked the top with a high frequency in lower, middle, upper Egypt (33.8%,26.8%,38.7% resp.).

    Women who developed breast cancer were more amenable than women who remained free of breast carcinoma to experience reduced physical function, vitality, social function.

    Difficulties related to sexuality and sexual functioning were common and occurred soon after surgical and adjuvant treatment. addressing these problems is essential to improve the quality of life of young women with breast cancer.

    Sexuality is a basic and important domain of human experience that can be damaged during and following cancer treatment. The risk of sexual dysfunction is even of greater importance among young cancer patients and survivors, with young breast cancer patients at particularly high risk.

    In cancer breast patients, various factors can induce sexual dysfunction. Some of these factors; hormonal alterations induced by chemotherapy and radiotherapy, or physiological and functional disturbances are related to the deterioration of physical condition. These factors are strictly clinical.

    Other factors which induce disturbances in sexual behavior, such as anxious\ depressive reactions in adapting to illness and treatment and cancerophobic reactions and loss of self esteem that accompany any illness are more psychological\ psychiatric in nature.

    Having sexual problems (or dysfunction) includes experiencing disturbances in sexual desire and physiological changes associated with loss of sexual desire and arousal, reduction in sexual pleasure, difficulty achieving orgasm, anxiety about sexual performance and pain during intercourse.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    75 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Evaluating Female Sexual Dysfunction in Breast Cancer Patients After Mastectomy
    Anticipated Study Start Date :
    Jul 1, 2017
    Anticipated Primary Completion Date :
    Jul 1, 2018
    Anticipated Study Completion Date :
    Dec 1, 2018

    Outcome Measures

    Primary Outcome Measures

    1. assessment of female sexual dysfunction in breast cancer patients after mastectomy using questionaire [one month]

      description of manner of female sexual dysfunction after mastectomy using Arabic Female Sexual Function Index and FEMALE SEXUAL FUNCTION INDEX DOMAIN SCORES AND FULL SCALE SCORE

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Age: 18-40 years old.

    • Social status: Married.

    • (Performance status): Who 0-1

    • 0-Asymptomatic (fully active, able to carry on all predisease activities without restriction)

    • 1-Symptomatic but completely ambulatory (restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature. For example, light housework, office work)

    Exclusion Criteria:

    • Pregnant women.

    • Comorbidities (Diabetes mellitus., Hypertension).

    • Female genital tract disease.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Hanaa H Bery, princilal investigator, Assiut University
    ClinicalTrials.gov Identifier:
    NCT03153631
    Other Study ID Numbers:
    • fsdbc
    First Posted:
    May 15, 2017
    Last Update Posted:
    May 16, 2017
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Breast Neoplasms

    Study Results

    No Results Posted as of May 16, 2017